[A22-121] Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) – Benefit assessment according to § 35a Social Code Book V
Last updated 15.02.2023
Project no.:
A22-121
Commission:
Commission awarded on 10.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adolescents 12 to < 18 years with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-94 | Tralokinumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |